| Document |
Document Title |
|
WO/1999/046279A2 |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...
|
|
WO/1999/044616A1 |
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromicin and novobiocin.
|
|
WO/1999/044621A1 |
Preventives/remedies for osteoporosis which contain phytoextrogen inhibiting reduction of bone density together with hardly digestible oligosaccharides. Owing to the combined use with the oligosaccharides, the effect of phytoextrogen of ...
|
|
WO/1999/042108A1 |
Selected steroids are used to produce pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system (CNS) without influencing other organs or systems. These steroids are characterised in tha...
|
|
WO/1999/041272A1 |
A method of isolating a purified tall oil sterol from neutral tall oil components, characterized by: (a) contacting the neutral tall oil components with at least one solvent selected from the group consisting of methanol, hydrous methano...
|
|
WO/1999/033768A1 |
This invention refers to the use of molecularly imprinted polymers as a method in which the selectivities of imprinted materials can be gainfully employed as binding matrices in the screening of combinatorial libraries.
|
|
WO/1999/032127A1 |
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
|
|
WO/1999/026962A1 |
An androgenic steroid compound of formula (I) wherein: X, Y, Z, R?1¿, R?2¿, R?3¿, R?5¿ and R?6¿ are as defined herein.
|
|
WO/1999/017779A1 |
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorationg pathologies...
|
|
WO/1999/013812A1 |
The present invention relates to transdermal dosage forms (10) for delivery of androgens.
|
|
WO/1999/013883A1 |
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and dev...
|
|
WO/1999/009050A1 |
Steroidal antagonists or agonists being complexes formed from (i) a transition metal or a non-transition metal Lewis acid and (ii) a receptor binding ligand capable of binding to a steroid receptor.
|
|
WO/1999/006057A1 |
A description is given of novel soya extracts having a defined ratio of soya saponins to glucoside isoflavones; processes for their production; and pharmaceutical compositions containing these extracts.
|
|
WO/1998/055497A1 |
The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having formulae (1), (2) and (3): HO-antibody-spacer-(A?2�)�n?, wherein A?1� is a moiety having formula (4); A?2� is a moiety having for...
|
|
WO/1998/055496A1 |
New non-estrogenic estradiol derivatives with an antioxidant effect are disclosed. These estradiol derivatives, which have no estrogenic effect but a high antioxidant effect, are potentially useful as non-estrogenic antioxidants, in part...
|
|
WO/1998/055074A2 |
The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgica...
|
|
WO/1998/050413A1 |
This invention provides a pharmaceutically acceptable salt of 3$g(b)-hydroxy-5(10)-estrene-17-one 3-sulfate ester and a pharmaceutically acceptable salt of 3$g(a)-hydroxy-5(10)-estrene-17-one 3-sulfate ester, which are useful as estrogens.
|
|
WO/1998/050412A1 |
This invention provides 3$g(b)-hydroxy-5,7,9-estratriene-17-one and a pharmaceutically acceptable salt of its 3-sulfate ester, which is useful as an estrogen.
|
|
WO/1998/045315A1 |
This invention provides estra-5(10),7-dien-3$g(b)-ol-17-one or a pharmaceutically acceptable salt of its 3-sulfate ester, estra-5(10),7-dien-3$g(b)-ol-17-one 3-glucuronide or a pharmaceutically acceptable salt thereof, estra-5(10),7-dien...
|
|
WO/1998/040398A1 |
Disclosed is a method of preparing a compound represented by structural formula (a). The method comprises reacting bromine (Br�2?) and an aliphatic organic acid with a compound represented by structural formula (b). R�1? and R�2? a...
|
|
WO/1998/039012A1 |
The invention relates to the use of a 7$g(a)-methyl-17$g(a)-ethynyl-estrane derivative having general formula (I) wherein R�1? = H(OR�3?) or O; R�2? = H or (C�1-18?)Acyl: R�3? = H or (C�1-18?)Acyl; and the dotted line represe...
|
|
WO/1998/034947A1 |
New 17$g(a)-fluoralkyl steroids have general formula (I), in which R?1� stands for a methyl or ethyl group; R?2� for a radical of formula C�n?F�m?H�o?, in which n equals 2, 3, 4, 5 or 6, m$m(g)1 and m+o = 2n+1; R?3� stands fo...
|
|
WO/1998/032718A1 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
WO/1998/031381A1 |
A method is provided for enhancing the cytoprotective effect of polycyclic phenolic compounds on a population of cells that involves the steps of administering a combination of polycyclic phenolic compounds and anti-oxidants to achieve a...
|
|
WO/1998/031702A1 |
The present invention relates to 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives according to formula (I), wherein R�1? is C�1-6?alkyl, C�3-6?cycloalkyl, C�1-6?alkoxy, triflate, pyridyl or phenyl where the phenyl m...
|
|
WO/1998/028322A1 |
Bissteroidal compounds of general formula (I), in which R�1? stands for hydrogen, alkyl, acyl, fluorine, and X�1?R�5?, where X�1? stands for oxygen and sulfur and R�5? can either be hydrogen, alkyl, aryl; R�2? stands for hydr...
|
|
WO/1998/025948A2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of formula (I) wherein: -A-A- represents the group -CHR?4�-CHR?5�- or -CR?4�=CR?5�-...
|
|
WO/1998/024448A1 |
A method of using a steroidal compound, 17$g(a)-dihydroequilenin, to prevent and treat neurodegeneration and cognitive dysfunction in estrogen deficient females and to reduce the risk of Alzheimer's related dementia and other senile deme...
|
|
WO/1998/016544A1 |
This invention provides 17$g(a),$g(D)8,9-dehydroestradiol or a pharmaceutically acceptable salt of its 3-sulfate ester, and 17$g(b),$g(D)8,9-dehydroestradiol or a pharmaceutically acceptable salt of its 3-sulfate ester.
|
|
WO/1998/016543A1 |
A remedy for chronic fatigue syndrome (CFS) containing dehydroepiandrosterone sulfate (DHAS) or a pharmaceutically acceptable salt thereof as the active ingredient. The administration of DHAS or its salt to a patient with CFS serves to s...
|
|
WO/1998/015279A1 |
The invention concerns the field of chemical therapy and more particularly the field of pharmaceutical hormonal technique. More precisely it concerns novel pharmaceutical hormonal compositions characterised in that they are formed by an ...
|
|
WO/1998/011123A1 |
Nucleosides and oligonucleosides functionalized to include carbamate functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophili...
|
|
WO/1998/005679A2 |
A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist. PR mixed agonists exhibit partial agonist activity which is influe...
|
|
WO/1998/004577A1 |
A process is disclosed for preparing 16$g(a)-hydroxy-estra-1,3,5(10)-triene derivatives having the general formula (I), in which R�1? stands for a hydrogen atom, an alkyl group with maximum 4 carbon atoms, a benzyl group or an acyl gro...
|
|
WO/1998/003137A1 |
A matrix type transdermal patch for coadministering estradiol and another steroid wherein the matrix is composed of a N-vinyl-2-pyrrolidone-containing acrylic copolymer pressure sensitive adhesive, estradiol, the other steroid, and optio...
|
|
WO/1998/002450A2 |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
WO/1997/049407A1 |
Disclosed is a contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units each containing as the sole contraceptively effective ingredient of a progestogen, or as effective ingredient for HRT a pr...
|
|
WO/1997/045441A1 |
The present invention relates to the novel 7'alpha'-(5-methylaminopentyl)-estratrienes of the general formula (I), in which R2 is a hydrogen or fluorine atom, R17 is a hydrogen atom, a methyl or ethynyl group, n is 2, 3 or 4, and x is 0,...
|
|
WO/1997/037664A2 |
Use is provided for a 7'alpha'-hydroxy or 7-oxo substituted 3'beta'-hydroxy-steroid possessing the carbon skeleton of cholesterol, androsterone, pregnenolone or estradiol, or an analogue thereof substituted independently at one or both o...
|
|
WO/1997/035824A1 |
A process for the preparation of fluorinated dicarbonyl compounds of general formula (2), comprising reacting dicarbonyl compounds of general formula (1) with fluorine gas without any solvent in the presence of one or more acids selected...
|
|
WO/1997/014696A2 |
The invention concerns compounds of general formulae (Ia) and (Ib), in which R1 and R2, which may be identical or different, designate hydrogen, C1-C6 lower alkyl, straight-chain or branched, or an aryl group, optionally substituted by e...
|
|
WO/1997/010255A1 |
Novel steriod esters useful for regulating skin atrophy, and skin maladies, as well as compositions containing the esters and methods for their use are described. A preferred steroid ester is DHEA salicylate. Such types of skin atrophy t...
|
|
WO/1997/003709A1 |
Described is an agent for transdermal application, characterized in that it contains esters of 13-ethyl-17'beta'-hydroxy-11-methylene-18,19-dinor-17'alpha'
-pregn-4-ene-20-yne-3-one with 1 to 20 carbon atoms in the ester group, optionall...
|
|
WO/1996/040152A1 |
The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgica...
|
|
WO/1996/040043A2 |
The invention relates to 3'alpha'-hydroxy, 17-(un)substituted derivatives of the androstane series and 3'alpha'-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified ...
|
|
WO/1996/035415A2 |
The invention relates to the use of a sesquiterpene for inhibiting an oxidative enzyme, preferably a cytochrome P450 enzyme. The invention also relates to compositions comprising a sesquiterpene and a drug which exhibits instability in t...
|
|
WO/1996/034846A1 |
Compounds of 1,3-propane diol linked structure (I), when for use in therapy, where R1 is an acyl or fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hy...
|
|
WO/1996/034855A1 |
Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or colu...
|
|
WO/1996/034858A1 |
Niacin as a compound, per se or for use in therapy, of structure (I), where B is -C(=O)- (nicotinic acid) or -CH2-O- (niacin alcohol), the "link" C which is optional is a diol or hydroxy carboxylic acid or dicarboxylic acid residue, and ...
|
|
WO/1996/028175A1 |
The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: (a) is extractable from bile of animals; (b) is cap...
|
